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The endoplasmic reticulum (ER) Hsp70 chaperone BiP is regulated by AMPylation, a
reversible inactivating post-translational modification. Both BiP AMPylation and deAMPyla-
tion are catalysed by a single ER-localised enzyme, FICD. Here we present crystallographic
and solution structures of a deAMPylation Michaelis complex formed between mammalian
AMPylated BiP and FICD. The latter, via its tetratricopeptide repeat domain, binds a surface
that is specific to ATP-state Hsp70 chaperones, explaining the exquisite selectivity of FICD
for BiP’s ATP-bound conformation both when AMPylating and deAMPylating Thr518. The
eukaryotic deAMPylation mechanism thus revealed, rationalises the role of the conserved Fic
domain Glu234 as a gatekeeper residue that both inhibits AMPylation and facilitates
hydrolytic deAMPylation catalysed by dimeric FICD. These findings point to a
monomerisation-induced increase in Glu234 flexibility as the basis of an oligomeric state-
dependent switch between FICD’s antagonistic activities, despite a similar mode of
engagement of its two substrates — unmodified and AMPylated BiP.
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The endoplasmic reticulum (ER) Hsp70, BiP, dominates thechaperoning capacity of the organelle1. BiP’s abundanceand activity are matched to the unfolded protein load of
the ER at the transcriptional level, by the canonical UPR, and also
post-translationally2. BiP AMPylation, the covalent attachment of
an ATP-derived AMP moiety to the Thr518 hydroxyl group, is
perhaps the best-defined BiP post-translational modification.
AMPylation inactivates BiP by biasing it towards a domain-
docked, linker-bound ATP-like Hsp70 state and away from the
domain-undocked, linker-extended ADP-like state3–5. As such,
AMPylated BiP (BiP-AMP) exhibits high rates of substrate dis-
sociation and is refractory to ATPase stimulation by J-domain
proteins3–5.
BiP AMPylation inversely correlates with the ER protein
folding load, increasing upon the inhibition of protein synthesis6
and with a resolution of ER stress3. Conversely, as ER stress
mounts, inactivated BiP-AMP is recruited into the chaperone
cycle by deAMPylation3,6,7.
A single bifunctional enzyme, FICD, is responsible for both
AMPylation3,8,9 and deAMPylation10–12 of BiP. FICD is the
metazoan exemplar of a family of bacterial Fic domain proteins13
whose canonical AMPylation activity14–16 is often autoinhibited
by a glutamate-containing alpha helix (αinh)17,18. In FICD, the
AMPylation-inhibiting Glu234 is also essential for
deAMPylation10. Moreover, monomerisation is able to recipro-
cally regulate FICD’s AMPylation/deAMPylation activity, con-
verting the dimeric deAMPylase into a monomeric enzyme with
primary BiP AMPylating functionality19. The recent discovery
that the Enterococcus faecalis Fic protein (EfFic) possesses
deAMPylation activity which is dependent on a glutamate
homologous to FICD’s Glu23412, suggests conservation of the
catalytic mechanism amongst Fic enzymes. However, the role of
Glu234 in the oligomeric state-dependent regulation of FICD’s
mutually antagonistic activities remains incompletely understood.
Fic domain proteins are unrelated to the two known bacterial
deAMPylating enzymes, SidD and the bifunctional GS-ATase.
Both catalyse binuclear Mg2+-facilitated deAMPylation reactions
of a hydrolytic20 and phosphorolytic21 nature, utilising a metal-
dependent protein phosphatase20 and a nucleotidyl
transferase22,23 protein-fold, respectively. Fic proteins have a
single divalent cation binding site and are evolutionarily and
structurally divergent from these deAMPylases and, therefore,
likely catalyse a distinct deAMPylation mechanism.
In addition to the aforementioned enzyme-based regulatory
mechanism(s), there is evidence that AMPylation is also regulated
by substrate availability (the concentration of free BiP:ATP). Cells
with a constitutively monomeric FICD retain a measure of
regulated BiP AMPylation19. FICD specifically binds and
AMPylates the domain-docked ATP-state of BiP3,19. Client
binding partitions Hsp70s away from their ATP-state, suggesting
a simple mechanism for coupling BiP AMPylation to low protein
folding loads. Furthermore, the finding that FICD selectively
AMPylates and deAMPylates ATP-state-biased BiP suggests that
FICD may recognise ATP-state specific features of its substrate in
a conserved binding mode, that is independent of FICD’s
oligomeric-state or BiP modification status.
Here we present a structure-based approach to determine the
nature of the FICD-BiP enzyme–substrate interaction, thereby
elucidating the mechanism of eukaryotic deAMPylation and the
basis for its regulation by an oligomerization-based switch in
FICD’s functionality.
Results
FICD engages AMPylated BiP via a bipartite interaction sur-
face. Mutation of the Fic motif catalytic histidine, which acts as an
essential general base in the AMPylation reaction14,15,24, eradi-
cates FICD’s deAMPylation activity10. Upon mutation of this
histidine (His363Ala), FICD and BiP-AMP formed a long-lived,
trapped deAMPylation complex19. This feature was exploited to
copurify FICD and AMPylated BiP by size-exclusion chromato-
graphy (SEC). A complex of otherwise wild-type dimeric
FICDH363A and AMPylated BiP readily crystallised, but despite
extensive efforts, these crystals did not yield useful diffraction data.
However, the introduction of a monomerising Leu258Asp muta-
tion and truncation of BiP’s flexible α-helical lid facilitated
purification of a heterodimeric FICDL258D-H363A·BiPT229A-V461F-
AMP complex (Supplementary Fig. 1a; see the “Methods” section)
that crystallised and produced two very similar sub-2 Å datasets
(Table 1).
The crystal structures displayed (identical) extensive bipartite
protein–protein interfaces totalling 1366 Å2 (Fig. 1a and Supple-
mentary Fig. 1b–d; state 1 crystal structure is shown). The
deAMPylation substrate, AMPylated BiP, is in a domain-docked
ATP-like state (despite lacking bound ATP), as reflected by the
similarity with the isolated ATP-state BiP-AMP structure4
(Fig. 1a; 1.02 Å root-mean-square deviation (RMSD) across all
521 Cα pairs). The FICD tetratricopeptide repeat domain motif 1
(TPR1) contacted a tripartite BiP surface (695 Å2), comprised of
its nucleotide-binding domain (NBD), interdomain linker and
substrate-binding domain-β (SBDβ) (Fig. 1b(i)). The interacting
residues located on FICD(TPR) are particularly well-conserved
across metazoan FICD homologues (Supplementary Fig. 1c).
The second interface, by which FICD’s catalytic Fic domain
engaged BiP’s SBDβ (671 Å2), contained an intermolecular









Space group P21212 P21212
Cell dimensions
a, b, c (Å) 95.37, 104.08, 105.63 95.00, 103.89, 104.79





Rmerge 0.085 (1.299) 0.087 (1.793)
<I/σI> 10.3 (1.2) 11.9 (1.0)
CC1/2 0.992 (0.585) 0.999 (0.536)
Completeness (%) 99.8 (99.3) 100.0 (100.0)
Redundancy 6.6 (6.5) 6.6 (6.9)
Refinement
Resolution (Å) 74.25–1.70 52.40–1.87











Bond lengths (Å) 0.003 0.003
Bond angles (°) 1.171 1.199
Both of the deAMPylation complexes contain human FICDL258D-H363A (residues 104–445)
bound to Chinese hamster BiPT229A-V461F-AMP (residues 27–549). Note, over the residue range
27–549 hamster and human BiP have identical amino acid sequences. Values in parentheses
correspond to the highest-resolution shell.
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Fig. 1 The deAMPylation complex crystal structure. a The deAMPylation complex crystal structure is colour-coded to illustrate its (sub)domain organisation.
The ATP-state structure of isolated BiP-AMP (PDB 5O4P, light grey)4 is superimposed via alignment of its NBD. See Supplementary Fig. 1b–d. b A focus on the two
intermolecular interaction surfaces. Selected interdomain contacting residues are shown. Polar interactions are depicted by pink dashed lines. Residues mutated in
this study are shown in green. i The interaction of FICD(TPR1) with the tripartite BiP surface (NBD-linker-SBDβ) is highlighted alongside the intramolecular contacts
between the FICD’s TPR and Fic domain. ii The intermolecular β-sheet formed between the Fic domain flap (brown) and the Thr518 bearing BiP(SBDβ) loop (ℓ7,8)
are highlighted. Note, this sequence-independent mode of substrate engagement is characteristic of Fic proteins15,18 (see Supplementary Fig 2). c Superposition of
two heterodimeric crystal structures (purple BiPs and yellow FICDs) with an FICD dimer structure (PDB 4U0U, grey)24. The α-helical BiP lid (SBDα, green, missing
from the heterodimeric crystal structure) is modelled by alignment with the full-length BiP:ATP structure (PDB 5E84)71. The N-terminal unstructured region of FICD
is shown in the context of an ER membrane24 (see Supplementary Movie 1).
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β-sheet between BiP’s Thr518-bearing loop (ℓ7,8) and the Fic
domain flap. The Fic domain flap has previously been implicated
in a similar sequence-independent recognition of AMPylation-
substrate or pseudo-substrate binding15,18 (Supplementary Fig. 2).
However, the previously observed, flap-mediated, hydrophobic
clamping of the AMPylation target residue15,18 is not observed
here, suggesting that this is not a universal feature of Fic-substrate
engagement (Supplementary Fig. 2c, d).
The AMP, covalently attached to BiP’s Thr518, was inserted
into the Fic domain active site, with the adenosine occupying the
same position as in FICD:nucleotide complexes19,24 (Fig. 1b(ii)
and Supplementary Fig. 1b). Contacts between the AMP moiety
and the FICD active site contributed an additional 306 Å2
interaction surface to the deAMPylation complex.
Monomeric FICD retains deAMPylation activity11,19, although
reduced relative to that of the dimeric enzyme19. Superposition of
two monomeric FICD-containing deAMPylation complexes
(state 1) with a dimeric FICD structure (PDB 4U0U; 2.58 Å
RMSD over 33 4Cα pairs across each FICD protomer)24,
demonstrates that the heterodimeric deAMPylation crystal
structure is readily accommodated in a hypothetical deAMPyla-
tion complex of dimeric FICD engaging two full-length BiP-AMP
molecules (Fig. 1c). The alignment also reveals a subtle intra-TPR
domain movement (especially in the TPR1 motif region) within
the substrate-bound FICD. This movement of the TPR1 motif
away from the Fic domain catalytic core likely results from the
direct interaction of FICD(TPR) with the tripartite BiP surface.
Furthermore, the modelled heterotetrametric complex is compa-
tible with FICD’s presumed orientation within the ER24,25, as it
can be readily anchored to the membrane via the extended
unstructured region linking FICD’s transmembrane and TPR
domains (Fig. 1c and Supplementary Fig. 1b).
The deAMPylation complex crystal structure is representative
of the internal arrangement of dimeric FICD engaged with
AMPylated BiP in solution. To assess the validity of the struc-
tural insights gained from the heterodimeric deAMPylation
complex crystal (obtained with monomeric FICDL258D-H336A and
a lid-truncated BiP-AMP), the properties of the intact protein
complex was analysed by a solution-based structural method.
Low-resolution structures of biomacromolecules can be resolved
by small-angle X-ray and neutron scattering (SAXS/SANS)26–29.
SAXS is sensitive to electron density, while SANS is sensitive to
atomic nuclei. For mixed complexes with two components,
contrast variation SANS is able to distinguish between proteins
that are differentially isotopically labelled27 and provide infor-
mation pertaining to protein complex size, shape and internal
arrangement with high precision26. To enable this analysis,
complexes of partially deuterated and non-deuterated dimeric
FICDH363A and full-length BiP-AMP were copurified by SEC into
buffers with varying D2O content. Contrast variation solution
scattering data were subsequently collected (Fig. 2a).
Analysis of the low-q Guinier region (Fig. 2b and Supplemen-
tary Fig. 3a) provided information pertaining to the forward
scattering, I(0), and radius of gyration, Rg, in each solution. The
former, along with the calculation of each complex’s contrast
match point (CMP; Fig. 2c), provided an estimate of the complex
molecular weight (Supplementary Table 1)—which was in good
agreement with a FICD·BiP-AMP 2:2 complex. The Stuhrmann
plot (derived from the square of the Rg data against the reciprocal
of the contrast)30 provided information on the internal arrange-
ment of the heterotetramer (assigning FICD to the inside of the
complex) and size (Rg) of the overall complex and its constituent
components (Fig. 2d); all of which are consistent with those
calculated from the modelled heterotetramer structure (Supple-
mentary Table 1, Fig. 1c and Supplementary Movie 1).
In addition, the relatively linear Stuhrmann plot shape derived
from the deAMPylation complex containing partially deuterated
FICD, suggests that this complex has a scattering length density
(SLD) centre which is very close to the complex’s centre of mass
(COM). The converse is true for the partially deuterated BiP
complex’s Stuhrmann fit that reveals no overlap between the
latter’s SLD centre and COM. As partial-deuteration of a
component increases its relative contribution to the SLD, these
findings are consistent with a heterotetramer in which the
complex centre of mass is closer to the centre of mass of the two
FICD molecules than the centre of mass of the two BiP molecules.
This arrangement fits well the structural model presented in
Fig. 1c and Supplementary Movie 1.
Moreover, across the entire scattering range and at all D2O
concentrations, the theoretical scattering profile of the hetero-
tetramer (modelled in Fig. 1c) nicely correlated with the observed
experimental scattering, producing an overall average χ2 of 3.3 ± 4
(mean ± standard deviation (SD)) or 2.4 ± 2 following anomalous
dataset removal (Fig. 2a and Supplementary Fig. 3b). This was
true even at D2O concentrations close to the CMP for each
deAMPylation complex, where the scattering profile is very
sensitive to both the shape and stoichiometry of the particles in
solution. Furthermore, the best flex-fit structure (generated for
each scattering dataset by allowing the input structure to undergo
normal mode flexing of its domains) did not drastically improve
model fitting (Fig. 1c, green dashed lines and Supplementary
Fig. 3b). The SANS data thus indicate that the vast majority of
particles in solution are engaged in a heterotetramer with neutron
scattering properties predicted by a model based on the
heterodimer crystal structure.
By analysing the data over the entire scattering q-range,
through flex-fitting, it is also possible to capture some of the
dynamics of the protein complex in solution (as demonstrated
recently29). Although no individual flex-fit structure produced a
significantly reduced average χ2 across all datasets, a number of
flex-fit output structures did have significantly different and
reduced χ2 variance (Supplementary Fig. 3c, underlined). The
majority of flex-fit structures possessed Rg parameters which were
in good agreement with the Stuhrmann-derived Rg values
(Supplementary Fig. 3d) and the principal variation in the flex-
fit structures was evident in BiP(NBD) and FICD(TPR) domain
reorientation and in the BiP lid region (Supplementary Fig. 3e, f).
Only around half of the flex-fit output structures maintained the
C2 rotational symmetry present in the input heterotetramer
structure (Supplementary Fig. 3c, d, bold), which stems from the
C2 symmetry of the FICD dimer. As symmetry is expected for an
average solution structure of a (symmetrical) dimeric FICD fully
occupied at two independent BiP-binding sites, each flex-fitting
strategy yielded one best-fit structure which was both symme-
trical and had a significantly reduced χ2 variance (Fig. 2e,
Supplementary Fig. 3g, c and d [bold and underlined] and
Supplementary Movie 1).
Interestingly, the best-fit structure derived from leaving the
high-affinity FICD dimer interface unconstrained (mean χ2
goodness-of-fit across the reduced data set 1.7 ± 0.4) maintains
an intact dimer interface and is in fact more similar in overall
conformation to the input structure than that obtained with a
restrained dimer-interface (mean χ2 2.4 ± 0.8), with an RMSD of
5.4 and 7.1 Å (across 1892 Cα pairs), respectively. Both output
structures demonstrate good Rg agreement with the Stuhrmann
analysis. Importantly, the complexes’ FICD Rgs are increased, and
in better agreement with the experimentally derived values,
relative to the input structure (Supplementary Fig. 3d and
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Heterotetramers’ centre of mass
Fig. 2 The DeAMPylation complex probed by small-angle neutron scattering (SANS). a Contrast-variation SANS curves of copurified dimeric FICD and
full-length AMPylated BiP. Overlaid dotted black lines are theoretical scattering curves based on the modelled heterotetramer shown in Fig. 1c, dashed
green lines are the theoretical scattering curves from flex-fitting of the input heterotetramer model to each scattering curve individually (with a constrained
FICD dimer interface) (see Supplementary Fig. 3b–e). In each experiment ‘d’ and ‘h’ refers to the partially deuterated and non-deuterated components,
respectively. Mean values are shown alongside error bars representing the standard error of the mean (SEM) calculated with respect to the number of
pixels used in the radial data averaging. b Guinier plot of partially deuterated FICD and non-deuterated AMPylated BiP (derived from the scattering data
shown in a, with mean ± SEM values plotted). Vertical, grey dotted lines represent the q-range for fitting the linear best-fit curves (black dashed lines) (see
Supplementary Fig. 3a). c Scattering amplitude plots. Linear best-fits are shown with dashed lines and 95% confidence interval bands are shown with
colour-matched solid lines. d Stuhrmann plot with best-fit dashed curves. 95% confidence prediction bands are shown with solid lines. The determined
match points of the individual complex components are indicated on the x-axis. In c and d best-fit values are shown alongside the standard errors of the
Guinier fit parameters. e Optimal flex-fit structures with respect to overall agreement of theoretical scattering to all experimental contrast-variation SANS
datasets. Output structures are aligned to the input heterotetramer model, itself derived by imposing the C2 symmetry of the FICD dimer (PDB 4U0U)24
onto the heterodimeric deAMPylation complex crystal structure as in Fig. 1c. See Supplementary Movie 1. Source data are provided as a Source Data file.
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Supplementary Table 1). In addition, the model derived from
flex-fitting without constraints on the FICD dimer interface (as
well as possessing the overall lowest average χ2 value and χ2
variance) also possesses a BiP Rg which is fully consistent with the
Stuhrmann analysis from both oppositely labelled deAMPylation
complexes (Supplementary Table 1). Therefore, the observed
model deviation is indicative of additional deAMPylation
complex flexibility in solution, in particular in the composite
FICD(TPR)–BiP(NBD) interface and in the disposition of the BiP
lid (Supplementary Movie 1). This flexibility is inaccessible to the
crystallographic analysis of BiP (complexes) but is consistent with
previous observations of Hsp70 conformational dynamics in the
Hsp70 ATP-state5,31.
Engagement of the FICD TPR domain with BiP-AMP is
essential for complex assembly and deAMPylation. To test the
importance of contacts between FICD’s TPR domain and BiP in
complex formation, catalytically inactive (His363Ala) but struc-
turally intact FICD variants (Supplementary Fig. 4a–c) were
analysed for their ability to interact with immobilised BiP by
BioLayer Interferometry (BLI). As FICD selectively binds to the
ATP-state of BiP19, BiP was pre-incubated with MgATP (Sup-
plementary Fig. 4d). Consistent with previous findings19, BiP
bound more tightly to monomeric FICDL258D-H363A than to
dimeric FICD. The converse was true for AMPylated BiP. As
noted previously19, complex dissociation was accelerated by the
presence of ATP in the dissociation buffer (Fig. 3a); likely a
reflection of an allosteric effect on FICD (when engaging
unmodified BiP:ATP)19, or competition for FICD’s active site
(when engaging BiP-AMP). Upon removal of the TPR1 motif,
dimeric FICD lost all appreciable binding to either BiP ligand,
whereas, the isolated TPR domain measurably interacted with
both BiP ligands irrespective of their modification status (Fig. 3a).
Mutation of residues at the FICD(TPR1)–BiP interface
significantly affected the association and dissociation of both
monomeric and dimeric FICD variants (Fig. 3b and Supplemen-
tary Fig. 4e). This agrees with the idea (supported by small-angle
scattering data) that monomeric and dimeric FICD similarly
engage AMPylated BiP. In keeping with the crystallographically
observed multivalent nature of the deAMPylation complex, the
biphasic kinetics of FICDL258D-H363A·BiP-AMP interaction
becomes more monophasic upon disruption of FICD(TPR1)–BiP
contacts (Fig. 3b(i)).
As previously observed19, FICD’s TPR domain can fully
disengage from the linker helix, exhibiting a ‘TPR-out’ con-
formation (PDB 6I7K and 6I7L)19. To analyze the effect of TPR
flexibility on FICD function, we artificially stabilised the BiP
binding-competent ‘TPR-in’ conformation by mutating Asp160
and Thr183 (Fig. 1b(i)) to cysteines and oxidising the protein to
form an intramolecular disulfide bond (TPRox, Supplementary
Fig. 4c). TPR oxidation within a monomeric FICDL258D-H363A
background resulted in more biphasic binding kinetics and a
significant decrease in dissociation rate from BiP-AMP (Fig. 3b
(i)). This suggested that the covalent fixation of the ‘TPR-in’
conformation outweighed any destabilising effects of perturbing
the precise alignment of the intramolecular Fic-TPR domain
contacts by mutagenesis. Indeed, oxidation of this protein
resulted in marked stabilisation relative to the cysteine reduced
form (TPRred), which also does not reversibly associate with BiP-
AMP (Supplementary Fig. 4b and f). Notably, the effect of TPRox
on dimeric FICD binding to BiP-AMP was less pronounced
(Fig. 3b(ii)).
The differential effects of TPRox on monomeric and dimeric
FICD is consistent with the ‘TPR-out’ conformation having been
observed only in monomeric FICD structures19 and suggests that
dimeric FICD has an intrinsically less flexible TPR domain.
Nevertheless, ‘TPR in’ fixation (by oxidation) does alter dimeric
FICD-binding kinetics: dissociation of dimeric FICD from BiP-
AMP is accelerated by TPR domain oxidation. The difference
between FICDH363A(TPRox) and FICDH363A dissociation rates is
further accentuated by the presence of ATP (Fig. 3b(ii) and
Supplementary Fig. 4e). This difference is presumably a
manifestation of the disruption of FICD’s interdomain TPR-Fic
contact— that results from the mutation of Asp160 and cannot be
rescued by intramolecular disulfide bond formation (Fig. 3b(i)).
This notion is further supported by the observation that TPRred
behaves similarly to TPRox in context of the dimeric FICD
(Supplementary Fig. 4f).
Consistent with the essential role played by the TPR domain in
deAMPylation complex assembly, mutation or removal of the
TPR1 motif significantly reduced the catalytic efficiency (kcat/KM)
of BiP-AMP deAMPylation, by both the monomeric and dimeric
enzymes in vitro (Fig. 3c, and Supplementary Fig. 5a–c).
Interestingly, although fixing the ‘TPR in’ conformation by
oxidation (TPRox) did not significantly diminish the affinity of
FICD for AMPylated BiP (Fig. 3b and Supplementary Fig. 4f), it
did compromise the deAMPylation activity of both monomeric
and dimeric FICD (Fig. 3c, bottom). This effect on catalytic
efficiency plausibly reflects a contribution of TPR domain
flexibility and intra-FICD interdomain communication to
deAMPylation turnover number (kcat).
FICD’s TPR domain is responsible for the recognition of
unmodified ATP-state BiP. The importance of contacts between
FICD’s TPR domain and BiP to deAMPylation, demonstrated
above, explains previous observations that the isolated AMPy-
lated BiP SBD is refractory to FICD-mediated deAMPylation10. It
is noteworthy that FICD also specifically binds19 and AMPylates
ATP-state BiP with a preference for more domain-docked BiP
mutants and fails to AMPylate the isolated BiP SBD3. Further-
more, the observation that FICD’s interaction with unmodified
BiP:ATP was abrogated by TPR1 deletion (Fig. 3a) suggests that
FICD recognises the ATP-state of unmodified BiP (for AMPy-
lation) in a similar fashion to ATP-state biased BiP-AMP (for
deAMPylation).
Structures of unmodified BiP indicate that a domain-undocked
ADP-state BiP loses the tripartite NBD-linker-SBDβ surface that
is recognised by FICD’s TPR1 motif in the context of
deAMPylation (Fig. 4a and Supplementary Movie 2). This
engagement is reminiscent of the ATP state-specific interaction
of J-domain proteins with Hsp70s (Supplementary Fig. 6a).
Furthermore, even if FICD were able to bind the NBD or the ℓ7,8
SBDβ region (which also becomes less accessible in BiP’s ADP-
state) of a nucleotide-free (apo) or ADP-bound BiP, the Hsp70’s
heavy bias towards the domain-undocked conformation5,32
would render engagement of the other FICD–BiP interaction
surface unlikely (Fig. 4a and Supplementary Movie 2).
Consistent with this structural analysis (Fig. 4a), the isolated
TPR domain of FICD was able to specifically bind the domain-
docked ATP-state of unmodified BiP with a KD of 1.1 µM
(Fig. 4b, c). Moreover, the lack of detectable interaction of the
domain-undocked BiP:Apo suggests that the KD of FICD’s TPR
domain for BiP:Apo must be >160 µM. The fast-on and fast-off
binding kinetics of the isolated TPR domain with ATP-state BiP
are in keeping with its role as a substrate recognition domain of
an enzyme evolved for efficient catalysis.
To further test the role of conserved TPR–BiP contacts in
formation of a pre-AMPylation complex (consisting of FICD and
BiP:ATP) we returned to the BLI setup of Fig. 3b, but with ATP-
bound unmodified BiP immobilised as a ligand. In this context
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Fig. 3 FICD’s TPR domain is essential for BiP-AMP binding and deAMPylation. a Representative BLI association–dissociation curves of FICD analytes from
immobilised BiP (either AMPylated or unmodified) bound to ATP (n= 3 independent experiments). See Supplementary Fig. 4d. b Representative BLI analysis of
TPR domain mutants of monomeric (i) and dimeric (ii) FICD binding to immobilised AMPylated BiP (n= 3 independent experiments). In both a and b the buffer
used in the second dissociation step (see vertical dashed lines) was supplemented with 2mM ATP. In b(ii) the second dissociation step traces (where
applicable) are overlayed with the best-fit curves derived from a two-phase exponential decay model. See Supplementary Fig. 4e, f. c Analysis of the
ability of different FICD variants to deAMPylate BiP. Left, Fluorescent polarisation-derived time courses of BiP-AMP(FAM) deAMPylation. Fits of the initial
linear reaction phase are overlaid. Right, quantification of the approximate catalytic efficiencies of the different FICD variants. Mean values of approximate
kcat/KM values for each FICD variant ± standard deviation (SD), from n= 4 independent experiments, are shown. See Supplementary Fig. 5. For reasons of
experimental expedience, the Glu105Arg FICD mutant was not incorporated into an enzymatically competent FICD background and was, therefore, neither
tested in this in vitro deAMPylation assay nor in the vitro AMPylation assays shown later (Fig. 5a). Source data are provided as a Source Data file.
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Fig. 4 FICD’s TPR domain is essential for the recognition of ATP-bound unmodified BiP. a The deAMPylation complex (coloured as in Fig. 1a with
selected BiP interaction partners labelled) is aligned via its NBD (i) or SBDβ (ii) with an ADP-state BiP (PDB 7A4U; grey)72. Inset (i), a closeup view of
FICD(TPR1)-BiP(NBD) contacts. (ii) the intermolecular β-sheet region of ℓ7,8 (green) is shortened in BiP:ADP. Inset, disposition of Thr518 is highlighted
(pink lines; hydrogen bonds). See Supplementary Movie 2 and Supplementary Fig. 6a. b FICD’s isolated TPR domain specifically binds the ATP-state of BiP.
A representative BLI experiment demonstrating the ability of FICD(TPR) to engage immobilised BiP:ATP but not BiP:Apo. A global fit analysis of a one-
phase association–dissociation model (black dashed lines) is overlaid. Below are the resulting kinetic binding parameters (mean ± SD) of the interaction of
FICD(TPR) and BiP:ATP, from n= 3 independent experiments. c Steady-state equilibrium binding response analysis of the representative TPR domain
binding experiment shown in b. Results from the analyte dilution series from the three independent BiP:ATP binding experiments are represented by
different symbols. The fit from a one site binding model is shown with 95% confidence bands (dashed black line and solid grey lines, respectively). The
calculated KD is also annotated (mean ± SD). The inset panel highlights the same data and fitting over the lower analyte concentration range. Note, the lack
of detectable steady-state binding of the TPR domain to BiP:Apo. d Representative BLI analysis of TPR domain mutants of monomeric (i) and dimeric (ii)
FICD binding to immobilised ATP-bound BiP, from n= 3 independent experiments. See Supplementary Fig. 6b. Source data are provided as a Source
Data file.
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the effects of TPR1 motif mutations on FICD binding were
magnified relative to their effect on the deAMPylation complex
(Fig. 4d and Supplementary Fig. 6b). This is consistent with a
greater contribution of FICD’s TPR domain to the assembly of
the pre-AMPylation complex compared to the deAMPylation
complex (as only the latter benefits from the interaction interface
between the covalently BiP-linked AMP moiety and FICD’s active
site). Loss of TPR–BiP contacts by surface mutations in TPR1 also
impaired BiP AMPylation by monomeric FICD in vitro (Fig. 5a
and Supplementary Fig. 6c), paralleling the effect of these
mutations on deAMPylation (Fig. 3). Fixation of the TPRin
conformation by TPR oxidation, although stabilising the pre-
AMPylation complex of monomeric FICD and BiP:ATP (Fig. 4d
and Supplementary Fig. 6b), nonetheless decreases the in vitro
AMPylation rate (Fig. 5a). Taken together, the effects of TPRox
suggest that TPR domain flexibility contributes to the kcat of both
AMPylation and deAMPylation.
To examine the effect of the TPR surface mutations on BiP
AMPylation in cells, we compared the ability of otherwise wild-
type, hyperactive, monomeric FICD lacking the gatekeeper
glutamate (FICDE234G-L258D) and TPR mutant versions thereof
to promote a pool of AMPylated BiP in cells lacking endogenous
FICD. Levels of AMPylated BiP, detected by its mobility on
native-PAGE, were significantly lower in cells targeted with the
FICDK124E-E234G-L258D and FICDK124E-H131A-E234G-L258D TPR1
mutations (Fig. 5b). The higher levels of expression of the TPR1
mutant FICDs, compared to the parental FICDE234G-L258D, is also
consistent with previous observations of an inverse relationship
between FICD variant expression level and AMPylation
activity19.
BiP inactivation, by deregulated AMPylation, increases ER
stress19. This feature was exploited to quantify the functional
effect of the TPR1 mutations in an orthogonal assay, based on the
ER stress-responsive reporter XBP1::Turquoise, utilising flow
cytometry (Fig. 5c and Supplementary Fig. 6d). In cells expressing
the various TPR1 mutant FICD derivatives, reporter activity
(analysed by its bimodal distribution) correlated well with the
levels of AMPylated BiP detected by native-PAGE and with the
hierarchy of the mutations’ effects on BiP binding (Fig. 3b).
The totality of these observations leads us to conclude that TPR
surface mutations in residues that contact BiP in the deAMPyla-
tion complex also contribute to enzyme–substrate interaction
during FICD-mediated AMPylation. Moreover, BiP’s Thr518 can
be readily modelled into the active site of a AMPylating
monomeric FICD alongside its MgATP co-substrate, by align-
ment with the deAMPylation complex’s Fic domain (Supple-
mentary Fig. 7). This provides further support for a similar mode
of FICD substrate engagement facilitating both of its mutually
antagonistic enzymatic activities.
The mechanism of eukaryotic deAMPylation. The requirement
for Glu234, His363 and the identification of AMP and unmodi-
fied BiP as products of the deAMPylation reaction10,19 led us to
previously propose a speculative model for the deAMPylation
reaction mechanism10. This subject has now been re-visited in
light of the functionally validated architecture of the high-
resolution eukaryotic deAMPylation complex.
The state 1 deAMPylation complex crystal structure contains
well-resolved electron density for BiP’s AMPylated Thr518
residue within FICD’s active site (Fig. 6a). The phosphate of
Thr518-AMP is coordinated by a Mg2+ held in position by
Asp367 of FICD’s Fic motif. A similarly positioned Mg2+
coordinates the α and β phosphates of ATP in the AMPylation-
competent enzyme19 and in FICD:MgADP (Supplementary
Fig. 2c). Glu234 (located atop the αinh helix) tightly engages a
water molecule located within FICD’s LR-type anion-binding
nest33 (Fig. 6a and Supplementary Fig. 8). The latter (Fic motif)
feature contributes towards the stabilisation of ATP’s α and β
phosphates in the AMPylating enzyme18,24.
The aforementioned Glu234-coordinated water molecule sits
almost directly in-line with the Pα-Oγ(Thr518) phosphodiester
bond (Fig. 6b, Supplementary Fig. 8 and Supplementary Movie 3)
and likely constitutes the hydrolytic water molecule. When also
modelled with a catalytic histidine (from PDB 6I7K; 0.45 Å
RMSD over 214 Cα pairs aligned over the Fic domain residues
213–426)19 the structure is highly suggestive of an acido-basic
hydrolytic mechanism: Glu234 aligns and activates a water
molecule for an SN2-type nucleophilic attack into the α-
phosphate, with His363 positioned to facilitate the concerted
protonation of the Thr518 alkoxide leaving group (generating
unmodified BiP and AMP as products10).
Increased Glu234 flexibility enfeebles monomeric FICD
deAMPylation activity. The deAMPylation complex active site
presented in Fig. 6 explains the essential role of gatekeeper
Glu234 in Fic domain-catalysed deAMPylation10,12. However, a
second sub-2 Å deAMPylation complex-crystal structure (refer-
red to as state 2), which is almost identical to that previously
presented (Table 1, Supplementary Fig. 9a and Supplementary
Movie 3), hints at an important detail. As in the state 1 structure
(Fig. 6), the FICD active site contains clear electron densities for
BiP’s Thr518-AMP, Fic domain catalytic residues and a coordi-
nated Mg2+ cation (Supplementary Fig. 9b). However, alignment
with the state 1 structure reveals a different orientation of Glu234
(Fig. 7a, Supplementary Fig. 9c and Supplementary Movie 3). In
the state 2 structure Glu234’s sidechain points away from the
position of the catalytic water molecule, clearly visible in state 1,
towards the Mg2+.
The variability in Glu234 conformation, noted above, fits previous
observations that FICD monomerisation increases Glu234 flexibility,
disfavouring autoinhibition of AMPylation activity19. The reorienta-
tion of Glu234 noted in state 2 also perturbs the proposed deAM-
Pylation mechanism by inducing a slight shift in the Mg2+
octahedral coordination complex (Fig. 7a and Supplementary
Movie 3). Although there is some remaining electron density in
the region of the catalytic water molecule noted in state 1, this
density is merged with that of a Mg2+-coordinating water molecule.
The elongated density is incompatible with the presence of two
water molecules (as accommodating the Mg2+-coordination
geometry would necessitate an infeasible inter-water distance of
1.89 Å) and suggests that there may be a dynamic shuttling of a
water to and from the primary Mg2+-coordination sphere into a
position conducive to catalysis. It is therefore clear that the Glu234
position observed in the state 2 crystal structure does not permit the
stable positioning of a catalytic water molecule in-line for
nucleophilic attack.
A corollary of the two tenets—that Glu234 is necessary for
coordinating a catalytic water molecule for deAMPylation and
that Glu234 flexibility increases upon monomerisation—is the
prediction that FICD-mediated deAMPylation activity should
decrease upon monomerisation. This has already been demon-
strated in terms of a 46% decrease in catalytic efficiency (Fig. 3c
and Supplementary Table 2)—the calculated kcat/KM of FICD is
1.9-fold (±0.2-fold (SEM)) greater than that of FICDL258D.
Moreover, dimeric FICD’s kcat/KM is in good agreement with that
derived from a previous Michaelis–Menten analysis of a GST-
tagged FICD10 (Supplementary Table 2).
However, an increase in Glu234 flexibility is also expected to
intrinsically affect deAMPylation catalysis and thus lower the kcat.
In order to directly measure the turnover number for monomeric
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and dimeric FICD both enzymes must be saturated with
deAMPylation substrate. It was found that the initial rates of
deAMPylation were indistinguishable at substrate concentrations
of 100 and 150 µM BiP-AMP (Fig. 7b and Supplementary Fig. 9d,
e), implying that FICD and FICDL258D are saturated by BiP-AMP
under the given experimental conditions. Therefore, at these
substrate concentrations the initial deAMPylation rates represent
maximal enzyme velocities, from which a kcat parameter can be
extracted (Fig. 7c). As expected for the less-flexible Glu234-






























































































































































































































































































































































































Fig. 5 FICD’s TPR domain is essential for AMPylation of ATP-bound BiP. a Fluorescence and Coomassie gel-images of an in vitro AMPylation assay,
utilising ATP(FAM) as the AMPylation co-substrate, in the presence of excess product trap (Trap(ox), to discourage BiP-AMP(FAM) deAMPylation10).
dFICD, dimeric FICD; mFICD, monomeric FICDL258D. Gels from a representative experiment are shown with the initial rates (mean ± 95% confidence
interval (CI)) of BiP-AMPylation (in relative fluorescent units/s), normalised to the rate of mFICD-mediated BiP-AMPylation, from n= 4 independent
experiments. Note, the lack of correlation between FICD (cis)auto-AMPylation and BiP substrate AMPylation. See Supplementary Fig. 6c. b Native-PAGE
immunoblot analysis of the accumulation of AMPylated (B-form) BiP in CHO cells lacking endogenous FICD transfected with FICD variants, as indicated.
Major, non-AMPylated BiP species (A, II and III) are noted. Right, quantification of AMPylated B-form BiP from n= 3 independent experiments (mean ±
SD). c Histograms of the FACS signal of an XBP1::Turquoise UPR reporter in FICD−/− CHO cells expressing the indicated FICD derivatives. Note the
bimodal distribution of the fluorescent signal in FICD-transfected cells. Quantification of the fraction of cells that are stressed, as well as the median FACS
signal of the low and high stressed cell populations are shown from n= 4 independent experiments (mean values ± SD). Bars and datapoints are (colour-)
coded according to the histogram legend. Source data are provided as a Source Data file.
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greater (by a factor of 1.8 ± 0.2) than that of monomeric
FICDL258D (Fig. 7c and Supplementary Table 2).
Together, the comparison of dimeric and monomeric FICD
deAMPylation catalytic efficiencies and turnover numbers
suggests that both oligomeric states of FICD possess very similar
KM values for BiP-AMP (16–17 µM, see Supplementary Table 2).
Thus, the increased deAMPylation kcat of dimeric FICD is
compensated for by the increased affinity of dimeric FICD for
BiP-AMP (see Fig. 3a). Note, the kcat and KM values derived for
dimeric FICD are in good agreement with those previously
obtained from Michaelis–Menten analysis of GST-FICD (Supple-
mentary Table 2) adding credibility to the method of kcat/KM and
kcat determinations presented here.
Discussion
Here, we have leveraged insights from crystal structures of a
deAMPylation complex of FICD and BiP-AMP to gain a detailed
understanding of eukaryotic deAMPylation and a broad
understanding of the enzyme–substrate interactions of FICD that
underpin its mutually antagonistic activities of BiP AMPylation
and deAMPylation. Biochemical and cellular studies of structure-
guided mutations in FICD have shed light on both substrate- and
enzyme-level regulation of BiP’s AMPylation cycle as it matches
BiP activity to ER stress in a post-translational strand of the UPR
(Fig. 8 and Supplementary Fig. 10).
The specific recognition of ATP-state BiP is mediated by an
interaction of FICD’s TPR1 domain with a tripartite ATP state-
specific surface composed of BiP’s NBD, linker and SBDβ.
Moreover, the TPR domain of FICD is only able to direct BiP’s
ℓ7,8 SBDβ region into the Fic domain active site when BiP’s
NBD and SBD are closely opposed, as in the domain-docked
ATP-state. These features explain the finding that the
client protein-bound ADP-state BiP is not a substrate for
AMPylation3 and suggests a facile mechanism for substrate-
level regulation of BiP AMPylation—in which substate avail-
























































Fig. 6 The enzymatic mechanism of eukaryotic deAMPylation. a BiP’s Thr518-AMP (purple) bound to FICD (yellow). Left, the arrangement of BiP’s
AMPylated Thr518 and Mg2+ cation within the Fic domain active site. Residues interacting with Mg2+ and the AMP moiety are shown as sticks and
annotated. Hydrogen-bonds involving the AMP moiety and FICD’s Glu234 sidechain are shown (with high confidence hydrogen bonds depicted with thick,
pink dashed lines and those only meeting relaxed hydrogen bond constraints depicted with orange dashed lines). Note, the putative catalytic water
molecule* forms hydrogen bonds to Glu234 (located at the top of αinh) and potential hydrogen bonds to the backbone NH groups of the Fic domain anion-
binding nest (G368NG370) and Arg371 (see Supplementary Fig. 8). Right, a slightly rotated view of the FICD-active site, shown on the left, overlaid with an
unbiased polder OMIT electron density map, contoured at 4σ. For clarity only hydrogen bonds formed by Glu234 are shown (pink dashed lines). b As in the
right-hand side of a but reduced to highlight Glu234’s coordination of the catalytic water molecule* and its position in-line for nucleophilic attack into the α-
phosphate. Additionally, the putative general acid, His363, is modelled based on an alignment of FICD:MgATP (PDB 6I7K, turquoise)19. See Supplementary
Movie 3.
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A reciprocal mechanism for substrate-level regulation of
deAMPylation is unlikely, as AMPylated BiP is intrinsically
biased towards the ATP-like domain-docked state4. Biochemical
and cell-based experiments, pointing to similar modes of BiP
engagement in FICD-mediated AMPylation and deAMPylation,
thus suggest that regulatory changes in FICD’s active site must
contribute to the enzyme’s ability to respond to changes in the
burden of ER unfolded proteins. Previous studies uncovered a
role for a monomerisation-induced increase in Glu234 flexibility,
which permits AMPylation competent binding of MgATP within
the FICD-active site19. However, the basis for the relationship
between oligomeric state and deAMPylation activity remained
obscure, awaiting clarification of the enzymatic mechanism
and the essential role played by Glu234 in FICD-mediated
deAMPylation.
Whilst this manuscript was in revision we became aware of a
crystal structure of BiP covalently bound to FICD (PDB
6ZMD)34, likely that of a transient intermediate post-AMPylation
state. This covalent complex possess a near-identical FICD
(TPR)–BiP interface to the deAMPylation complexes presented
here, which accounts for the consistent outcome of the muta-
genesis carried out in both studies. However, due to mutations
a
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FICD•BiP-AMP (State 2, incompetent)
FICD•BiP-AMP (State 1, competent)
FICD:MgATP
Fig. 7 Monomerisation increases the likelihood of a non-deAMPylation competent Glu234 conformation. a An unbiased polder OMIT electron
density map from a second deAMPylation complex structure (state 2), contoured at 6σ, covering selected Fic domain catalytic residues (orange), the
Mg2+-coordination complex and BiP’s Thr518-AMP (green). The reduced (state 2) active site is aligned with the active site of the (deAMPylation
competent) state 1 complex (yellow). His363 is modelled from an alignment of catalytically competent FICD (PDB 6I7K, as in Fig. 6b)19. Residues
interacting with the AMP moiety are shown as sticks and the catalytic water (from state 1) is annotated with *. The distance between the Mg2+ first-
coordination sphere water (red, state 2) and the (state 1) catalytic water* is annotated. Hydrogen bonds formed by Glu234 are shown as pink dashed lines.
See Supplementary Movie 3 and Supplementary Fig. 9a–c. b A representative BiP-deAMPylation time course with 10 µM FICD or FICDL258D, demonstrating
that 100 and 150 µM BiP-AMP both represent saturating concentrations of deAMPylation substrate. See Supplementary Fig. 9d, e. c The derived kcat
parameters, from n= 4 independent experiments each with two saturating concentrations of BiP-AMP (as in b). The mean ± SD is shown with the P-value
from a two-tailed Welch’s t-test annotated. Source data are provided as a Source Data file.
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introduced into the FICD in question (FICDL258D-E234G-E404C)
and the nature of the covalent capture strategy employed (which
corrupts the interface of the Fic domain and BiP(SBDβ)), the
covalently linked FICD–BiP complex provides no details per-
taining to FICD’s enzymatic mechanism (Supplementary Fig. 11).
The crystal structures presented in this work provide strong
support for a mechanism of eukaryotic deAMPylation that is
acido-basic in nature and in which Glu234 aligns a catalytic water
molecule in-line for an SN2-type nucleophilic attack into α-
phosphate of Thr518-AMP (Supplementary Fig. 10). Glu234, may
act as a catalytic (but not a general) base through a mechanism
involving late proton transfer analogous to the role played by the
catalytic aspartates of some protein kinases35,36. This proposed
deAMPylation mechanism (which also rationalises the essential
role for a divalent cation and His363) is far removed from the
binuclear metal-catalysed reactions catalysed by the other two
known (bacterial) deAMPylases20,23. Moreover, other mechan-
isms of phosphodiester bond cleavage, including anchimeric
assistance or an E1cB-type elimination reaction, which are cap-
able of generating the products of FICD-mediated deAMPylation
(AMP and unmodified BiP), are rendered very unlikely by the
structure of the deAMPylation complex (Supplementary Fig. 8
and Fig. 6a).
As a bacterial Fic protein (EfFic) has also been observed to
possess gatekeeper glutamate-dependent deAMPylation
activity12, it is likely that the mechanism of deAMPylation out-
lined above is conserved across this class of proteins. This con-
clusion, pertaining to the immediate role of Glu234 in enabling
BiP-AMP hydrolysis, permits various inferences to be made about
the role of monomerisation and increased Glu234 flexibility in the
regulation of deAMPylation activity. These, are supported by the
direct observation of a monomeric FICD–deAMPylation complex
with an alternative Glu234 conformation, resulting in a (state 2)
deAMPylation non-competent active site that lacks a stably
coordinated catalytic water molecule. Thus, increased Glu234
flexibility, induced by FICD monomerisation, not only con-
siderably increases AMPylation activity19 (Fig. 5a) but also
decreases the deAMPylation kcat (Fig. 7c).
Oligomeric-state changes in the disposition of the gatekeeper
Glu234 may not be the only mechanism for enzyme-based reg-
ulation of the BiP AMPylation–deAMPylation cycle. Observa-




































































Fig. 8 Model of FICD AMPylation and deAMPylation of BiP. FICD’s TPR domain and catalytic Fic domain recognise, respectively, the linker-docked NBD
and the ℓ7,8 region of the SBDβ of either AMPylated or unmodified BiP. Simultaneous engagement of both interfaces is only possible when BiP is in a
domain-docked ATP-like state. Dimeric FICD has a relatively rigid gatekeeper Glu234 that facilitates efficient alignment of an attacking water for BiP
deAMPylation and inhibits AMPylation competent binding of ATP. Enhanced flexibility of monomeric FICD’s Glu234 decreases deAMPylation efficiency
whilst permitting AMPylation competent binding of MgATP by monomeric FICD. We speculate that the FICD monomer-dimer equilibrium is adjusted in
response to changing levels of unfolded proteins within the ER by processes which may include a direct response to changes in the ER energy status (ATP/
ADP ratio)19. Further details of the FICD-catalysed deAMPylation reaction are presented in Supplementary Fig. 10.
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than BiP-AMP and the converse being true for dimeric FICD19
(Fig. 3a), remain unexplained by the structure of the FICD
deAMPylation complex. Modelling of the AMPylation complex
active site does implicate oligomeric state-linked changes in
Glu234 flexibility in directly contributing to the observed differ-
ential substrate-binding affinities (Supplementary Fig. 7b).
However, it is entirely possible that other as yet unidentified
differences in the interactions between FICD and BiP are medi-
ated by changes in FICD oligomeric state or BiP modification
status or by FICD protein dynamics. Indeed, a role for the latter is
hinted at by the crystallographic and SANS-based evidence for
TPR domain flexibility and by the effects of TPR fixation on
enzyme–substrate complex formation and catalysis.
These caveats notwithstanding, this study advances our
mechanistic understanding of the reciprocal-regulation of enzy-
matic activity afforded by FICD’s oligomerisation-state-
dependent switch (Fig. 8). This leaves unanswered the question
of if and how the FICD monomer–dimer equilibrium responds to
changing conditions in the ER. There is some evidence that FICD
may respond to the energy-status of the ER, as a proxy for ER
stress19. Given that Hsp70 proteins can directly modulate the
oligomeric status (and thus activity) of their own regulators
within the ER37 and cytosol/nucleus38 (BiP/Ire1α and Hsc70/
Hsf1, respectively), the possibility of an additional layer of BiP-
driven FICD-regulation is therefore an intriguing one to consider.
Methods
Plasmid construction. The plasmids used in this study have been described pre-
viously or were generated by quick change polymerase chain reactions [annotated
as ‘QC’ primers in Supplementary Table 4], Q5 site-directed mutagenesis (NEB)
using Q5 Hot Start High-Fidelity DNA Polymerase (NEB) according to the
manufacturer’s protocol, or restriction digestion and ligation into existing plas-
mids. Full lists of the utilised plasmids and primers are provided in Supplementary
Tables 3 and 4, respectively.
Protein purification. All proteins were purified using the method for FICD protein
expression detailed in ref. 19, with only minor modifications. In brief, proteins were
expressed as N-terminal His6-Smt3 fusion constructs from either pET28-b vectors
(expressed in T7 Express lysY/Iq (NEB) Escherichia coli (E. coli) cells), or pQE30
vectors (expressed in M15 E. coli cells (Qiagen)). T7 Express cells were grown in LB
medium containing 50 µg/ml kanamycin. M15 cells were grown in the same
medium supplemented with an additional 100 µg/ml ampicillin. All cells were
grown at 37 °C to an optical density (OD600nm) of 0.6 and then shifted to 18 °C for
20 min, followed by induction of protein expression with 0.5 mM isopropylthio β-
D-1-galactopyranoside (IPTG). Cells were harvested by centrifugation after a fur-
ther 16 h at 18 °C.
Only the predicted structured regions of human FICD were expressed (residues
104–445). For ‘full-length’ BiP constructs, that is to say constructs containing the
complete structured region of the SBDα lid subdomain, residues 27–635 of Chinese
hamster BiP were expressed. This excludes an unstructured acidic N-terminal
region and the C-terminal unstructured region bearing the KDEL. Note, in the
recombinantly expressed residue range hamster and human BiP are identical in
terms of amino acid identity. For use as an immobilised BLI ligand full-length BiP
was expressed with an avi-tag inserted C-terminal to Smt3 and N-terminal to a GS
linker and hamster BiP residues 27–635.
All BiP constructs used in this study were made ATPase39 and substrate-
binding40 deficient via introduction of Thr229Ala and Val461Phe mutations,
respectively. Thr229Ala allows BiP to bind and domain-dock in response to
MgATP, even when immobilised via an N-terminal biotinylated Avi-tag19. The
lack of ATP hydrolysis enables BiP to remain bound to ATP in its domain-docked
state for prolonged periods of time, a feature which favours binding to19 and
AMPylation by FICD3. Both Thr229Ala (in the presence of ATP) and Val461Phe
(independent of nucleotide) disfavour the binding of proteins within BiP’s SBD
(which principally occurs in the apo or ADP-state).
Following harvesting and lysis of the bacterial pellets, proteins were purified
through the use of Ni-NTA agarose (Thermo Fisher), on-bead Ulp1 cleavage, anion
exchange and gel filtration chromatography (based on the protein purification
method within19). All purification was conducted at 4 °C. Unless otherwise
specified (below) anion exchanges were conducted using a RESOURCE Q 6ml
column (GE Healthcare) with a linear gradient ranging from 95% AEX-A (25 mM
Tris–HCl pH 8.0) and 5% AEX-B (25 mM Tris–HCl, 1 M NaCl) to 50% AEX-A
and 50% AEX-B (see Supplementary Table 3). Gel filtration was conducted,
depending on protein size and amount, on either a HiLoad 16/60 Superdex 75 or
200 prep grade column or a S200 or S75 Increase 10/300 GL column (see
Supplementary Table 3). All proteins were purified to homogeneity and >95%
purity, as assessed by Coomassie-stained SDS–PAGE. Unless the protein was
deliberately oxidised they were supplemented after gel filtration with 1 mM tris(2-
carboxyethyl)phosphine (TCEP). Proteins were concentrated to >150 µM using
centrifugal filters (Amicon Ultra; Merck Millipore), aliquoted and snap-frozen and
stored at −80 °C. All protein concentrations were calculated using A280, measured
on a NanoDrop One (Thermo Fisher), and the protein’s predicted extinction
coefficient at 280 nm (ε280).
Preparative BiP AMPylation. In the case of preparative scale AMPylation of BiP,
this was achieved post-Ulp1 cleavage by addition of 10 mM MgCl2, 5 mM ATP and
1/50 (w/w) GST-TEV-FICDE234G (UK147919). The AMPylation reaction was
incubated for 16 h at 25 °C. GST-TEV-FICD was then depleted by a 1 h incubation
with GSH-Sepharose 4B matrix (GE Healthcare). AMPylation was confirmed as
being stoichiometric by intact-protein mass spectrometry (LC-ESI-MS)4.
Forming disulfide-linked FICD dimers. Disulfide-linked FICD dimers
(s-sFICDA252C-H363A-C421S; UK2269)19, used as a BiP-AMP trap for in vitro
AMPylation assays, were purified as above with modifications. In brief, after the
affinity chromatography step and the on-column Upl1-StrepII cleavage, the
retained cleavage products were washed off the beads with TN-Iz10 (25 mM
Tris–HCl pH 8.0, 150 mM NaCl, 10 mM imidazole) in the absence of reducing
agent. The pooled eluate was concentrated and diluted 1:4 with TN-Iz10 (to further
reduce the TCEP concentration). To allow for efficient disulfide bond formation
the samples were supplemented with 20 mM oxidised glutathione and for 16 h at
4 °C. Afterwards, the protein solutions were diluted 1:2 with 25 mM Tris–HCl pH
8.0 and further purified by anion exchange and size-exclusion chromatography, as
above. The final s-sFICDA252C-H363A-C421S preparations were analysed by non-
reducing SDS–PAGE to confirm quantitative formation of covalently linked dimers
(>95%).
In vitro biotinylation of BiP. In vitro biotinylation of N-terminally avi-tagged BiPs
was conducted on the expression tag-cleaved forms of unmodified or AMPylated
BiPT229A-V461F residues 27–635 (UK2359). Biotinylation was conducted with
100 µM target protein, 200 µM biotin (Sigma) and 2 µM GST-BirA (UK1801) in a
buffer of 2 mM ATP, 5 mM MgCl2, 25 mM Tris–HCl pH 8.0, 150 mM NaCl and
1 mM TCEP. The reaction mixture was incubated for 16 h at 4 °C. The protein was
made nucleotide-free by the addition of 2 U calf intestinal alkaline phosphatase
(NEB) per mg of BiP, plus extensive dialysis into TN buffer supplemented with
1 mM DTT and 2mM EDTA. The protein was then incubated with 0.5 ml GSH-
Sepharose 4B matrix, for 1 h at 4 °C, to deplete the GST-BirA. The biotinylated
BiP-containing supernatant was diluted 1:1 with AEX-A and loaded onto a MonoQ
5/50 GL column (GE Healthcare), equilibrated in 92.5% AEX-A and 7.5% AEX-B.
BiP protein was eluted using a linear gradient of 7.5–50% AEX-B, over 20 CV at a
flow rate of 1 ml/min. The Mono Q eluted protein fractions were supplemented
with TCEP, diluted with glycerol and stored at –20 °C in a final buffer of TNTG
(12.5 mM Tris–HCl pH 8.0, ~150 mM NaCl, 0.5 mM TCEP and 50% (v/v) gly-
cerol) at a concentration >1 µM. Protein samples were validated as being
nucleotide-free (apo) by their A260/280 ratio and reference to IP-RP-HPLC
analysis10. Proteins were confirmed as being >95% biotinylated via a streptavidin
gel-shift assay.
FICD TPR domain oxidation. Purification of TPR domain oxidised (TPRox)
FICDD160C-T183C-C421S-derivative proteins was achieved as above (for other
FICDs), with the addition of an oxidation and clean-up AEX step. Note, the
cysteine free FICDC421S mutation was previously observed to have no effect on
FICD-mediated deAMPylation or BiP-AMP binding and a slight stimulatory effect
on FICD-mediated AMPylation19.
In order to form the disulfide bond, the FICD protein (post-Ulp1 cleavage
and Ni-NTA column elution) was diluted down to a concentration of 5 µM in a
final buffer of 25 mM Tris–HCl pH 8.0 and 100 mM NaCl, supplemented with
0.5 mM CuSO4 and 1.75 mM 1,10-phenanthroline (Sigma), and incubated for 16
h at 4 °C. The oxidation reaction was then quenched by the addition of 2 mM
EDTA. The protein solution, diluted with 25 mM Tris pH 8.0 to a final NaCl
concentration of 50 mM, was then purified on a HiTrap 5 ml Capto Q column
(equilibrated in 95% AEX-A and 5% AEX-B buffer) using a linear gradient of
5–50% AEX-B over 10 column volumes. Proteinaceous fractions were further
purified as detailed above (beginning with RESOURCE Q column purification),
culminating in the purification of dimeric or monomeric FICD (as appropriate)
by gel filtration.
Stoichiometric disulfide bond formation was confirmed by the use of an
electrophoretic mobility assay (see Supplementary Fig. 4c), in which the putatively
oxidised protein was heated for 10 min at 70 °C in SDS–Laemmli buffer ± DTT; all
available thiols were then reacted with a large excess of PEG 2000 maleimide (30
min at 25 °C). All unreacted maleimides were then quenched by the addition of a
molar excess of DTT before samples were analysed by SDS–PAGE. Significant PEG
modification of FICD(TPRox) proteins was only observed in samples first
denatured in reducing conditions (+DTT), suggesting that the two TPR domain-
cysteines were not accessible for alkylation in the absence of DTT (on account of
being oxidised to form an intramolecular disulphide bond).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25076-7
14 NATURE COMMUNICATIONS |         (2021) 12:5004 | https://doi.org/10.1038/s41467-021-25076-7 | www.nature.com/naturecommunications
Protein crystallisation and structure determination. Monomeric
FICDL258D-H363A (residues 104–445) [UK2093] and monomeric lid-truncated
BiPT229A-V461F-AMP (residues 27–549) [UK2090] were purified as above and gel
filtered into a final buffer of T(10)NT (10 mM Tris–HCl pH 8.0, 150 mM NaCl and
1 mM TCEP). As outlined in the text, FICD’s His363Ala mutation facilitates a
stable trapping of its deAMPylation substrate. As mentioned above, BiPT229A-V461F
favours its monomeric ATP-state, in which it is less likely to bind substrates in its
SBD and to form BiP oligomers. The removal of all but helix A of the SBDα (BiP
residues 27–549) was also implemented to reduce the affinity of BiP substrate
binding and oligomerisation and to increase the likelihood of crystallisation and
high-resolution diffraction by removal of the flexible SBDα helix B, which in other
Hsp70s has been documented to only transiently interact with the NBD in the
ATP-state31. Heterodimer copurification was achieved by mixing FICDL258D-H363A
and BiPT229A-V461F-AMP in a 1.5:1 molar ratio, supplemented with an additional
250 µM ATP, 50 mM KCl and 2 mMMgCl2. The mixture was incubated for 10 min
at 4 °C and purified by gel filtration on an S200 Increase 10/300 GL column
equilibrated in TNKMT buffer (10 mM Tris–HCl pH 8.0, 100 mM NaCl, 50 mM
KCl, 2 mM MgCl2 and 1 mM TCEP) with ≤5 mg of protein injected per SEC run.
Heterodimeric protein fractions were pooled (as indicated in Supplementary
Fig. 1a) and concentrated to 10.3 mg/ml using a 50 kDa MWCO centrifugal filter.
Crystallisation solutions, consisting of 100 nl protein solution and 100 nl
crystallisation reservoir solution, were dispensed using a mosquito crystal (SPT
Labtech) and the complex was crystallised via sitting drop vapour diffusion at
25 °C. State 1 crystals were obtained from reservoir conditions of 0.1 M MES pH
6.5, 10% PEG 4000 and 0.2 M NaCl; state 2 crystals were obtained from conditions
of 0.1 M Tris pH 8.0 and 25% PEG 400. Crystals were cryoprotected in a solution
consisting of 25% glycerol and 75% of the respective reservoir solution (v/v).
Diffraction data were collected from the Diamond Light Source at 100 K
(beamline I04-1) utilising the Generic Data Acquisition (GDA) software (v9.2,
Diamond Light Source). The crystallography datasets were indexed, integrated and
scaled using xia2 software41 through either the DIALS42 (state 1 crystal) or XDS43
(state 2 crystal) processing pipelines. The resulting unmerged data was then further
processed by Pointless (for space group determination) and Aimless (for scaling
and merging), both part of the CCP4 module Aimless (CCP4i2 [v1.0.2])44,45.
Structures were solved by molecular replacement using the CCP4 module
Phaser44,46. AMPylated BiP (PDB 5O4P)4 and monomeric FICD (PDB 6I7L)19
structures from the Protein Data Bank were used as initial search models. Manual
model building was carried out in COOT47 and refined using refmac548 with TLS
added. Metal binding sites were validated using the CheckMyMetal server49. Zero
Ramachandran outliers were present in either crystal structure with 98.37% and
98.49% of residues falling within Ramachandran favoured regions (for the state 1
and state 2 complex, respectively). The respective MolProbity scores were 0.81
(100th percentile score) and 1.04 (100th percentile score).
Polder (OMIT) maps were generated using the Polder Map module of Phenix50,51.
Structural figures were prepared using UCSF Chimera52 and PDB structures with
evolutionary conservation score depictions were taken from the ConSurf Database53
(https://consurfdb.tau.ac.il/), estimates of interaction surface areas were derived from
PISA analysis54, interaction maps (Supplementary Figs. 1d and 8) were based on an
initial output from LigPlot+55 and the chemical reaction pathway (Supplementary
Fig. 10) was created in ChemDraw (PerkinElmer Informatics).
Contrast variation small angle neutron scattering. Non-deuterated
BiPT229A-V461F-AMP (residues 27–635) and FICDH363A (residues 104–445) [hBiP-
AMP and hFICD] were purified as detailed above but were gel filtered into a final
buffer of TNKMT(0.2) [TNKMT buffer with TCEP reduced to 0.2 mM]. The
matchout deuterium-labelled protein equivalents were produced in the ILL’s
deuteration laboratory (Grenoble, France). Proteins were expressed from E. coli
BL21 Star (DE3) cells (Invitrogen) that were adapted to 85% deuterated Enfors
minimal media containing unlabelled glycerol as carbon source56,57, in the pre-
sence of kanamycin at a final concentration of 35 µg/ml. The temperatures at which
the cells produced the highest amount of soluble matchout-deuterated BiP or FICD
were chosen for cell growth using a high cell density fermentation process in a
bioreactor (Labfors, Infors HT). For BiP expression, cells were grown using a fed-
batch fermentation strategy at 30 °C to an OD600 of 20. The temperature was then
decreased to 18 °C and protein expression was induced by addition of 1 mM IPTG.
After a further 22 h of protein expression at 18 °C, bacteria were harvested by
centrifugation. FICD expression was conducted likewise, but with induction at
OD600 19 and at a temperature of 22 °C. FICD-expressing cells were incubated for a
further 21.5 h at 22 °C before harvesting. Matchout-deuterated proteins
(dBiPT229A-V461F-AMP and dFICDH363A) were isolated and purified from deut-
erated cell pastes using H2O-based buffer systems, as mentioned above, and gel
filtered into TNKMT(0.2).
Heterotetrameric complexes were copurified by gel filtration of a mixture of
either dBiP-AMP and hFICD or hBiP-AMP and dFICD (in a 1.25:1 molar ratio of
BiP-AMP:FICD), with ≤5 mg of protein injected per SEC run, supplemented with
250 µM ATP. The gel filtration was conducted on an S200 Increase 10/300 GL
column equilibrated with TNKMT(0.2) buffer. Heterotetrameric complex fractions
were collected and concentrated to >7 mg/ml. Some of this purified complex was
further exchanged by the same SEC process into TNKMT(0.2) in which the solvent
used was D2O. That is to say, the complex was exchanged into 100% D2O buffer.
Protein fractions in 100% D2O buffer were subsequently concentrated to >6 mg/ml.
The elution profile appeared largely identical in both deuterated and non-
deuterated buffers. Complexes at different %D2O were obtained by either dilution
with the appropriate matched buffer (± D2O) or by the mixing of one complex
purified in 0% D2O buffer with the same complex in 100% D2O buffer.
SANS data were collected from a total of 17 samples at various D2O buffer
compositions at 12 °C at the ILL beamline D11. Protein complexes (ranging from 4.3
to 5.5mg/ml) were analysed in a 2mm path-length quartz cell with a 5.5 Å
wavelength neutron beam at distances of 1.4, 8 and 20.5m. Data from relevant buffer-
only controls were also collected with similar data collection times and subtracted
from the radially averaged sample scattering intensities to produce the I(q) against q
scattering curves presented in Fig. 2a. Scattering data were initially processed with the
GRASP (Graphical Reduction and Analysis SANS Programme for Matlab; developed
by Charles Dewhurst, ILL) and with the Igor Pro software (WaveMetrics) using SANS
macros58. Data analysis was conducted using Prism (v8.4, GraphPad) and PEPSI-
SANS (for fitting of theoretical scattering curves; software based on PEPSI-SAXS28).
Flexible fitting model generation was also implemented through PEPSI-SANS
software (https://team.inria.fr/nano-d/software/pepsi-sans/). In order to generate the
best flex-fit model for each scattering curve a nonlinear rigid block (NOLB) normal
mode analysis (NMA) method, utilising an all-atom anisotropic network model
(ANM)59, was employed. In brief from the starting input model (Fig. 1c) 100 models
were sampled from along the 10 lowest frequency NMA trajectories. The derived
models, after energy minimisation, were assessed for improved fit to the
experimentally obtained scattering data. The best fitting model was then selected for a
further round of NOLB NMA, as above. Iterative re-computation of the normal
modes was carried out in this fashion for a total of 10 cycles. Rigid blocks (for NOLB
NMA-based flex-fitting) were defined as BiP’s NBD, SBDβ and SBDα and FICD’s Fic
domain, α-helical linker and TPR domain (see Fig. 1a and Supplementary Fig. 1b). In
addition, a rigid block was defined as encompassing both Fic domains of the (dimeric)
input structure in order to facilitate the flex-fitting analysis with a constrained FICD
dimer interface (Fig. 2 and Supplementary Fig. 3, as indicated). Note, the utility of
NOLB NMA has recently been demonstrated in both its ability to capture biologically
relevant collective as well as localised protein transitions present in solution structures
(and not captured in crystallo) without perturbing local protein geometry60.
Comparison of the ln(Transmission) of the 0% and 100% D2O buffers alone
with the ln(Transmission) of each sample confirmed that the %D2O of each sample
was within the margin of error of the theoretical D2O content61.
Parameters from the Guinier plots were derived from fitting of the Guinier
approximation62:





The upper and lower q limits for fitting are shown (grey, vertical dashed lines in
Fig. 2b and Supplementary Fig. 3a—except for the fitting of hFICD·dBiP-AMP in
60% D2O buffer where the lower q limit (qmin) is denoted by a purple, vertical
dashed line). These fitting ranges resulted in 0.15 < qminRg < 0.57 and 0.39 < qmaxRg
< 1.3 (with the exception of the fitting of dFICD·hBiP-AMP in 80% D2O buffer
data where qmaxRg= 1.4).
The contrast match point analysis (CMP) in Fig. 2c indicated complex match
points of 76.7% D2O (95% confidence interval (CI): 71.5–82.4% D2O) and 61.4%
D2O (95% CI: 57.4–65.5% D2O) for hFICD·dBiP-AMP and dFICD·hBiP-AMP,
respectively. Comparison of the experimental CMPs with theoretical values
calculated by MULCh63 (which takes into account buffer composition effects (at
20 °C) and protein sequence, whilst assuming a 1:1 complex and 95% labile H/D-
exchange) suggested that there was 66.5% deuteration of dBiP-AMP and a 63.8%
deuteration of dFICD. Note, these calculated values of non-exchangeable hydrogen
deuteration are in-line with those expected from the 85% deuterated media and
non-deuterated carbon source E. coli growth conditions, see above. For instance,
under the same growth conditions, maltose-binding protein was found to be 64%
deuterated at non-exchangeable hydrogens by intact protein mass spectrometry57.
These values of dBiP-AMP and dFICD (non-labile) protein (partial)
deuteration were used to calculate theoretical I(0)/c values in SASSIE64, using the
same assumptions as above. Comparison of the theoretical I(0)/c values with those
determined from the experimental Guinier analysis facilitated experimental
protein-complex MW estimation27 (Supplementary Table 1). The contrast at each
%D2O (the difference in scattering length density (SLD), Δρ, between the ρprotein
and ρbuffer) was also derived from MULCh.
Stuhrmann analysis was carried out by the fitting of the relationship30:
Rg






In which Rm2 represent the protein complex Rg if it were to have a homogenous
SLD. The value of α reflects the radial distribution of SLD, with values
>0 suggesting that higher contrast components are located towards the outside of
the complex and vice versa. The value of β reflects the distance of the centre of the
complex’s SLD from the complex’s centre of mass. In the case of the Stuhrmann
plot of dFICD·hBiP-AMP a linear best-fit line (suggesting β ≈ 0) was a considerably
better fit to the data (shown in Fig. 2d; R2= 0.93) than the fitting of a quadratic
curve (R2= 0.66). Theoretical Rg values, derived from structural models, were
calculated using CRYSON65. The symmetry of structural models was assessed
through the use of AnAnaS software66.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25076-7 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:5004 | https://doi.org/10.1038/s41467-021-25076-7 |www.nature.com/naturecommunications 15
Differential scanning fluorimetry (DSF). DSF experiments were performed on a
CFX96 Touch Real-Time PCR Detection System (Bio-Rad) in 96-well plates (Hard-
Shell, Bio-Rad) sealed with optically clear Microseal ‘B’ Adhesive Sealer (Bio-Rad).
Each sample was measured in technical duplicate and in a final volume of 20 µl.
Protein was used at a final concentration of 2 µM, ATP or ADP (if applicable) at 5
and 2 mM, respectively, and SYPRO Orange dye (Thermo Fisher) at a 10× con-
centration in a buffer of HKM (25 mM HEPES–KOH pH 7.4, 150 mM KCl, 10 mM
MgCl2). Solutions were briefly mixed and the plate spun at 200 × g for 10 s before
DSF measurement. Fluorescence of the SYPRO Orange dye was monitored on the
FRET channel over a temperature range of 25–90 °C with 0.5 °C intervals (each
lasting 5 s). Background fluorescence changes were calculated and subtracted from
the protein sample fluorescence data using no-protein control (NPC) wells. NPC
fluorescence was unchanged by the addition of ATP or ADP. Data was then
analysed in Prism (v8.4, GraphPad), with melting temperatures calculated from the
global minimums of the negative first derivatives of the relative fluorescent unit
(RFU) melt curves (with respect to temperature).
Bio-layer interferometry (BLI). AMPylated or non-AMPylated biotinylated-
AviTag-haBiPT229A-V461F (UK2359), was AMPylated if applicable, in vitro bioti-
nylated, made apo and purified as detailed above in the section “Protein pur-
ification”. Both proteins were confirmed as being >95% biotinylated by streptavidin
gel-shift. All BLI experiments were conducted on the FortéBio Octet RED96 Sys-
tem (Pall FortéBio) using a buffer basis of HKM supplemented with 0.05% Triton
X-100 (HKMTx). Streptavidin (SA)-coated biosensors (Pall FortéBio) were
hydrated in HKMTx for at least 30 min at 25 °C prior to use. Experiments were
conducted at 30 °C. BLI reactions were prepared in 200 µl volumes in 96-well
microplates (greiner bio-one).
In Figs. 3 and 4 ligand loading was performed with biotinylated BiP-AMP:Apo
at 7.5 nM and with biotinylated BiP:Apo at 5.8 nM, such that the rate of ligand
loading was roughly equivalent and all tips reached a threshold of 1 nm binding
signal (displacement) within 300–600 s. All ligands loaded with a range of 1.0–1.2
nm. After loading of the immobilised ligand, BiP was activated in 2 mM ATP for
200 s. This was followed by a 50 s baseline in HKMTx alone, before association
with apo FICD variants (all bearing a catalytically inactivating His363Ala mutation
and at 50 nM unless otherwise specified) in HKMTx (see schematic in
Supplementary Fig. 4d). A no analyte reference biosensor was used to control for
baseline drift. Note, immobilised (unmodified) BiP was previously observed to
domain-dock, and remain domain-docked for extended periods of time in ATP-
replete buffer, following this protocol of ATP activation19. The first dissociation
step was initiated by the dipping of all tips into wells lacking FICD analyte (only
HKMTx). The second dissociation step was induced by the dipping of the
biosensor tips into HKMTx supplemented with 2 mM ATP. In Fig. 3b(ii) the
second dissociation step was analysed by fitting a two-phase exponential decay,
assuming a final plateau value of 0 nm. Experiments were conducted at a 1000 rpm
shake speed and with a 5 Hz acquisition rate.
Analysis of the binding of the isolated TPR domain (UK2051) to unmodified
BiP (Fig. 4b, c) was conducted as outlined above but with some modification. The
ligand, biotinylated BiP:Apo (at 11.6 nM), was loaded onto the biosensor to ≥1.8
nm. Following a 50 s baseline in HKMTx the biosensor (bearing BiP:Apo) was
dipped into a well solution containing 16 µM TPR domain for 50 s, followed by a
50 s dissociation step (also in HKMTx buffer). The same biosensor then underwent
a 200 s activation step (by dipping into an HKMTx buffer supplemented with 2
mM ATP). This was proceeded by a 10 s baseline step in HKMTx and then
sequential 50 s association and 50 s dissociation steps of the BiP:ATP bound
biosensor into increasing concentrations of TPR domain (from 62.5 nM to 16 µM).
Between each 100 s association–dissociation cycle a 10 s re-activation (in HKMTx
plus 2 mM ATP) and subsequent 10 s baseline (in HKMTx) was carried out.
Experiments were conducted at a 400 rpm shake speed and with a 10 Hz
acquisition rate and a parallel no ligand reference biosensor was used to control for
any non-specific analyte binding signal. All BLI data were processed in Prism (v8.4,
GraphPad). In Fig. 4b the BiP:ATP-binding traces were analysed by global fitting of
a one-phase association–dissociation-binding model (assuming a shared value of
kon, koff and Bmax). In Fig. 4c the steady-state equilibrium binding response data
was analysed by fitting a one site specific binding model. Equilibrium binding
response was calculated by averaging the binding signal between 45 and 49.9 s in
each association step (and adjusted relative to the initial level of BiP ligand loading
on the biosensor after the first 50 s baseline step—between 1.8–2.0 nm). The lower
estimate of the KD of FICD(TPR) for BiP:Apo was reached assuming that the same
number of immobilised BiP:Apo and BiP:ATP molecules would possess equivalent
maximum FICD(TPR)-binding potentials (Bmax values), whilst noting that binding
of FICD(TPR) to BiP:ATP was detectable at an analyte concentration of <0.1 × KD
and that no binding of 16 µM FICD(TPR) to immobilised BiP:Apo was observed.
In vitro deAMPylation (fluorescence polarisation) assay. The probe BiPT229A-
V461F (UK2521) modified with FAM-labelled AMP:BiPT229A-V461F-AMP(FAM))
was generated by pre-incubating 100 µM apo BiPT229A-V461F with 5 µM GST-
FICDE234G (UK1479) and 110 µM ATP in HKM buffer for 5 min at 20 °C, followed
by addition of 100 µM ATP-FAM [N6-(6-Amino)hexyl-ATP-6-FAM; Jena
Bioscience] and further incubation for 19 h at 25 °C. To ensure complete BiP
AMPylation 2 mM ATP was then added to the reaction which was incubated for a
further 1.25 h at 25 °C. The reaction mixture was then incubated with GSH-
Sepharose 4B matrix for 45 min at 4 °C in order to deplete the GST-FICDE234G.
The BiP containing supernatant was buffered exchanged into HKM using a Zeba
Spin desalting column (7 K MWCO, 0.5 ml; Thermo Fisher) in order to remove the
majority of free (FAM labelled) nucleotide. 2 mM ATP was added to the eluted
protein and incubated for 15 min at 4 °C (to facilitate displacement of any residual
FAM-labelled nucleotide derivates bound by the NBD of BiP). Pure BiP-AMP
(FAM) with BiP-AMP was then obtained by gel filtration using an S75 Increase 10/
300 GL column equilibrated in HKM at 4 °C. 1 mM TCEP was added to the protein
fractions, which were concentrated using a 50 K MWCO centrifugal filter and snap
frozen. A labelling efficiency of 1.8% was estimated based on the extinction coef-
ficient for BiP-AMP:ATP (ε280 33.5 mM−1 cm−1), FAM (ε492 83.0 mM−1 cm−1)
and a 280/492 nm correction factor of 0.3 (Jenna Biosciences).
DeAMPylation reactions were performed in HKMTx(0.1) buffer [HKM
supplemented with 0.1% (v/v) Triton X-100] in 384-well polysterene microplates
(black, flat bottom, µCLEAR; greiner bio-one) at 30 °C in a final volume of 30 µl
containing trace amounts of fluorescent BiPT229A-V461F-AMP(FAM) probe (10
nM), supplemented with BiPT229A-V461F-AMP (5 µM) and FICD proteins (0.5 µM).
A well lacking FICD protein was used for baseline FP background subtraction. 10
nM ATP-FAM alone was also included as a low FP control. Under these conditions
[E]0 was assumed to be << [S]0+ KM (with [E]0= 0.5 µM, [S]0= 5 µM and the
presumed KM (Michaelis constant) ≥GST-FICD KM of 16 µM10) such that quasi-
steady-state reaction kinetics should apply with respect to the initial reaction rate.
Furthermore, [S]0 was considered to be sufficiently small relative to the FICD
variant presumed KM values such that, by derivation from the Michaelis–Menten
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where v0 is the measured initial reaction velocity. On account of the close
correspondence between the values calculated here and previously (from a
Michaelis–Menten analysis of GST-FICD10) these assumptions are clearly valid for
wild-type FICD. More accurately all presented ~ kcat/KM values are in fact
equivalent to kcat/(KM+ [S]0).
Fluorescence polarisation of FAM (λex= 485 nm, λem= 535 nm) was measured
with an Infinite F500 plate reader (Tecan). The mFP y0 difference between the
FICDL258D time course and the same reaction composition pre-incubated for 5 h at
25 °C before the beginning of data collection, was interpreted as the ΔmFP
equivalent to complete (5 µM) BiP-AMP deAMPylation (see Supplementary
Fig. 5a). Fitting of the initial linear reaction phase was achieved using Prism (v8.4,
GraphPad).
For direct calculation of kcat values deAMPylation assays were conducted as
above but with 10 µM FICD or FICDL258D and 100 or 150 µM BiP-AMP substrate.
Following subtraction of a no enzyme background from all datasets, the mFP
difference for each sample (between t= 0 and the mFP plateau) was interpreted as
the ΔmFP equivalent to complete BiP-AMP deAMPylation ([S]0).
In vitro AMPylation. In vitro AMPylation reactions were performed in HKM
buffer in a 7 µl volume. Reactions contained 10 µM ATP-FAM, 5 µM ATP-
hydrolysis and substrate-binding-deficient BiPT229A-V461F (UK2521), 7.5 µM oxi-
dised S-SFICDA252C-H363A-C421S (UK2269, trap) to sequester any modified BiP
[BiP-AMP(FAM)] and, unless otherwise stated, 0.5 µM FICD. Reactions were
started by addition of nucleotide. Apart from the presented time courses (Sup-
plementary Fig. 6c) after a 60 min incubation at 25 °C the reactions were stopped
by addition of 3 µl 3.3 × LDS sample buffer (Sigma) containing NEM (40 mM final
concentration) for non-reducing SDS–PAGE or DTT (50 mM final concentration)
for reducing SDS–PAGE and heated for 10 min at 70 °C. Samples were applied to
an SDS–PAGE gel and the FAM-label was imaged with a Chemidoc MP (Bio-Rad)
using the Alexa Flour 488 dye setting. Gels were subsequently stained with Quick
Coomassie (Neo Biotech).
Mammalian cell culture and lysis. The CHO-K1, CHO-K1 FICD−/−, CHO-K1
S21 FICD−/− cell lines used in this study were described previously3. Cells were
cultured in Nutrient mixture F-12 Ham (Sigma) supplemented with 10% (v/v)
serum (FetalClone II; HyClone), 1 × Penicillin–Streptomycin (Sigma), and 2 mM L-
glutamine (Sigma) at 37 °C and 5% CO2. Cells were grown on tissue culture dishes
or multi-well plates (Corning) and experiments were performed at cell densities of
60–90% confluence. Cell lines were confirmed as being free of Mycoplasma con-
tamination by random testing using the MycoAlert Mycoplasma Detection Kit
(Lonza). Where indicated, cells were treated for 3 h with cycloheximide (Sigma) by
exchanging the culture medium with pre-warmed (37 °C) medium supplemented
with cycloheximide at 100 µg/ml. Cell lysates were obtained and analysed as in19
but with a HG lysis buffer consisting of 20 mM HEPES–KOH pH 7.4, 150 mM
NaCl, 2 mM MgCl2, 33 mM D-glucose, 10% (v/v) glycerol, 1% (v/v) Triton X-100
and protease inhibitors (2 mM phenylmethylsulphonyl fluoride (PMSF), 4 µg/ml
pepstatin, 4 µg/ml leupeptin, 8 µg/ml aprotinin) with 100 U/ml hexokinase (from
Saccharomyces cerevisiae Type F-300; Sigma).
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Immunoblot (IB) analysis. After separation by SDS–PAGE or native-PAGE19
proteins were transferred onto PVDF membranes. The membranes were blocked
with 5% (w/v) dried skimmed milk in TBS (25 mM Tris–HCl pH 7.5, 150 mM
NaCl) and incubated with primary antibodies diluted in 3% (w/v) BSA in TBS
supplemented with 0.1% Tween-20 (TBST). Primary antibodies and antisera
against hamster BiP [chicken anti-BiP68], eIF2α [mouse anti-eIF2α69] and FICD
[chicken anti-FICD3] were used at a dilutions of 1/1000, 1/5000 and 1/1000 (v/v),
respectively. Following the primary antibody incubation, the PVDF membrane was
washed with TBST and then incubated with IRDye fluorescently labelled secondary
antibodies (LI-COR) at a dilution of 1/2000 (v/v) in a solution of 3% (w/v) dried
skimmed milk in TBS. The membranes were scanned with an Odyssey near-infra-
red imager (LI-COR). Where applicable, IB band quantification was carried out
with Image Studio Lite software (LI-COR).
Flow cytometry. FICD over-expression-dependent induction of unfolded protein
response signalling was analysed by transient transfection of CHO-K1 S21 FICD−/−
UPR reporter cell lines with plasmid DNA encoding the complete FICD coding
sequence (with mutations as indicated) and mCherry as a transfection marker, using
Lipofectamine LTX (Thermo Fisher). 0.5 µg DNA was used to transfect cells
growing in 12-well plates. 40 h after transfection the cells were washed with PBS and
collected in PBS containing 4 mM EDTA, and single live-cell fluorescent signals
(20,000 collected per sample) were analysed by dual-channel flow cytometry with an
LSRFortessa cell analyser utilising FACSDiva acquisition software (BD Biosciences).
Turquoise and mCherry fluorescence was detected using a 405 nm excitation laser
with a 450/50 nm emission filter and a 561 nm excitation laser with a 610/20 nm
emission filter, respectively. Data were processed using FlowJo X (BD Bioscience)
and the extracted population parameters were plotted in Prism (v8.4, GraphPad).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The deAMPylation complex crystal structures of monomeric FICD and AMPylated BiP
have been deposited in the Protein Data Bank (PDB) with the following accession codes:
7B7Z (state 1) and 7B80 (state 2). Crystal structure data from previous studies are also
available in the PDB, deposited with the following accession codes: 5O4P, 4U0U, 5E84,
7A4U, 6I7K, 6I7L and 6ZMD. Raw SANS data is available from https://doi.org/10.5291/
ILL-DATA.8-03-96370. Source data are provided with this paper.
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